Taizhou city's Qyuns Therapeutics lists shares in Hong Kong

Qyuns Therapeutics, a biotech company based in Taizhou city – located in East China's Jiangsu province – started trading on the Hong Kong Stock Exchange on March 20.

Established in 2015, the company focuses on autoimmune and allergic disease therapies, boasting independent drug development and large-scale production capabilities.

It has a diverse product pipeline covering dermatology, rheumatology, respiratory and digestive fields – achieving leading advances in research and commercialization.

Chairman and CEO Qiu Jiwan said he chose the Taizhou Medical High-tech Zone as the company's base in 2007, drawn by its entrepreneurial culture and supportive environment.

As of March 2, Qyuns Therapeutics was among China's top players in autoimmune and allergic disease research, with promising candidates targeting conditions like psoriasis and atopic dermatitis.

Its lead product, QX001S for psoriasis, is set to have its domestic launch in 2024 after gaining regulatory approval.

The group is also collaborating with the Huadong Medicine Group to expand its market reach and expedite commercialization efforts, a move that is said to reflect its commitment to sustainable growth.

A wide view of the smart premises of Qyuns Therapeutics in Taizhou. [Photo/WeChat ID: tzfabu]

Staff members discuss research and development issues. [Photo/WeChat ID: tzfabu]